Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
JANSSEN PHARMACEUTICAL K.K.
🇯🇵
Japan
Country
🇯🇵
Japan
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News
A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)
Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
Drug: JNJ-26866138 0.7 mg/m2
Drug: JNJ-26866138 1.0 mg/m2
Drug: JNJ-26866138 1.3 mg/m2
Drug: Melphalan
Drug: Prednisolone
Subscribe
First Posted Date
2009-09-29
Last Posted Date
2013-12-02
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
101
Registration Number
NCT00985959
Subscribe
An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease
Phase 3
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo
Drug: Galantamine 16 mg/day
Drug: Galantamine 24 mg/day
Subscribe
First Posted Date
2008-12-25
Last Posted Date
2014-04-17
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
580
Registration Number
NCT00814801
Subscribe
Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants
Phase 2
Completed
Conditions
Pain
Cancer
Interventions
Drug: Tapentadol PR
Subscribe
First Posted Date
2008-12-09
Last Posted Date
2013-07-29
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
78
Registration Number
NCT00805142
Subscribe
A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome
Phase 1
Completed
Conditions
Myelodysplastic Syndrome
Interventions
Drug: JNJ-30979754 15 mg/m2
Drug: JNJ-30979754 20 mg/m2
Subscribe
First Posted Date
2008-11-24
Last Posted Date
2013-12-09
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
39
Registration Number
NCT00796003
Subscribe
An Efficacy and Safety Study of Fentanyl in Participants With Chronic Pain
Phase 3
Completed
Conditions
Chronic Pain
Interventions
Drug: Fentanyl
Subscribe
First Posted Date
2008-11-10
Last Posted Date
2013-06-26
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
142
Registration Number
NCT00788372
Subscribe
A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection
Phase 3
Completed
Conditions
Mycoses
Candidiasis
Aspergillosis
Cryptococcosis
Blastomycosis
Histoplasmosis
Neutropenia
Interventions
Drug: ITCZ Oral Solution
Drug: ITCZ-IV
Subscribe
First Posted Date
2008-11-02
Last Posted Date
2013-07-25
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
55
Registration Number
NCT00784368
Subscribe
A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)
Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: CNTO 148
Drug: Placebo
Subscribe
First Posted Date
2008-10-13
Last Posted Date
2015-11-03
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
311
Registration Number
NCT00771251
Subscribe
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
Phase 1
Completed
Conditions
Refractory
Multiple Myeloma
Relapse
Subscribe
First Posted Date
2008-09-15
Last Posted Date
2011-05-17
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
35
Registration Number
NCT00752518
Subscribe
An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain
Phase 2
Completed
Conditions
Osteoarthritis
Low Back Pain
Subscribe
First Posted Date
2008-09-15
Last Posted Date
2011-05-17
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
119
Registration Number
NCT00752661
Subscribe
An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain
Phase 3
Completed
Conditions
Pain
Interventions
Drug: Tramadol Hydrochloride Plus Acetaminophen (Open-Label)
Drug: Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)
Drug: Placebo (Double-Blind)
Subscribe
First Posted Date
2008-08-18
Last Posted Date
2013-09-26
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
321
Registration Number
NCT00736853
Subscribe
Prev
1
9
10
11
12
13
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy